Researchers have found in a new study that semaglutide could provide cardiovascular benefits to high-risk patients even ...

"Cleared after 38 yrs" is the headline for the Daily Mirror, which describes Peter Sullivan's ordeal as a "justice fiasco".

A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...

Rahul Dhanda, co-founder and president of biopharmaceutical company Syntis Bio, said that if a patient took the pill one ...

Fact checked by Nick Blackmer Tirzepatide and semaglutide, the ingredients in popular weight loss drugs, can both cause side ...

In addition to requests for double-digit premium increases, Blue Cross Blue Shield of Vermont is also cutting back on coverage of popular weight-loss drugs on some plans.

A first-in-human study of an investigational once-daily oral treatment for obesity (SYNT-101) demonstrated positive preliminary data for the safe and ...

New animal research being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), reveals distinct metabolic ...

People who take Wegovy appear to be at greater risk for hair loss, according to an early study that hasn't yet been ...

Trump is benefiting from the medical infrastructure the government has built up, while simultaneously destroying that infrastructure for everyone else.

Vivani Chief Executive Officer Adam Mendelsohn, Ph.D., stated, "Our ongoing first-in-human study, LIBERATE-1, remains on track to deliver key data in mid-2025 with the aim of validating our ...

Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.